Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Te-Sheng Chang

Showing results (131-140 of 138) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 138 results.
The Kaohsiung Journal of Medical Sciences|January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in TaiwanSzu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registryTyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.
Infectious Diseases and Therapy|April 28, 2024
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in TaiwanChun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, et al.
Hepatology International|January 21, 2024
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from TaiwanMing-Lung Yu, Chi-Ming Tai, Lein-Ray Mo, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 6, 2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in TaiwanChing-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, et al.
Clinical and Molecular Hepatology|January 9, 2024
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry programMing-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, et al.
Infectious Diseases and Therapy|December 30, 2021
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in TaiwanPin-Nan Cheng, Lein-Ray Mo, Chun-Ting Chen, et al.
Viruses|February 26, 2022
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting AntiviralsYen-Chun Chen, Te-Sheng Chang, Chien-Hung Chen, et al.
Pageof 14

Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
The Kaohsiung Journal of Medical Sciences|January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in TaiwanSzu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registryTyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.
Infectious Diseases and Therapy|April 28, 2024
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in TaiwanChun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, et al.
Hepatology International|January 21, 2024
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from TaiwanMing-Lung Yu, Chi-Ming Tai, Lein-Ray Mo, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 6, 2022
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in TaiwanChing-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, et al.
Clinical and Molecular Hepatology|January 9, 2024
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry programMing-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, et al.
Infectious Diseases and Therapy|December 30, 2021
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in TaiwanPin-Nan Cheng, Lein-Ray Mo, Chun-Ting Chen, et al.
Viruses|February 26, 2022
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting AntiviralsYen-Chun Chen, Te-Sheng Chang, Chien-Hung Chen, et al.
Pageof 14